Allergan was Editas Medicine’s largest revenue line in fiscal 2018, bringing in $21.50M of $31.90M (67%).
| Counterparty Name | FY 2015 | FY 2017 | FY 2018 |
|---|---|---|---|
| Allergan | — | $8.80M | $21.50M |
| Juno Therapeutics | $1.60M | $4.90M | $6.40M |
| Beam Therapeutics, Inc | — | — | $4.00M |
| Total | $1.60M | $13.70M | $31.90M |
Editas Medicine brought in $31.90M from its three revenue lines in fiscal 2018, the year ended December 31, 2018. Editas Medicine regrouped these revenue lines after fiscal 2017, so the total does not compare directly with that year's $13.70M. Allergan was the largest at $21.50M (67.4%), ahead of Juno Therapeutics at $6.40M (20.1%) and Beam Therapeutics, Inc at $4.00M (12.5%).
Compared with fiscal 2017, Allergan grew 144.3% to $21.50M and Juno Therapeutics grew 30.6% to $6.40M.
Editas Medicine began breaking out Allergan in fiscal 2017 and Beam Therapeutics, Inc in fiscal 2018.
As Originally Reported Under Topic 606 was Editas Medicine’s largest revenue line in fiscal 2018, bringing in $33.99M of $31.94M (106%).
| Initial Application Period Cumulative Effect Transition | FY 2018 |
|---|---|
| As Originally Reported Under Topic 606 | $33.99M |
| Effect Of Change | -$2.06M |
| Total | $31.94M |
Editas Medicine brought in $31.94M from its two revenue lines in fiscal 2018, the year ended December 31, 2018. As Originally Reported Under Topic 606 was the largest at $33.99M (106.4%).
The total is net of Effect Of Change, which took $2.06M off revenue in fiscal 2018.
Editas Medicine (EDIT) reports its revenue by counterparty name and by initial application period cumulative effect transition. In fiscal 2018, Allergan was its largest revenue line, bringing in $21.50M (67.4% of the total), followed by Juno Therapeutics at $6.40M (20.1%).
Allergan was Editas Medicine's largest revenue line in fiscal 2018, bringing in $21.50M, or 67.4% of the $31.90M total across its three revenue lines.
Every figure comes from Editas Medicine's annual financial filings, as reported. Each line keeps the name Editas Medicine gives it, and years follow its fiscal calendar.
Editas Medicine's revenue by counterparty name goes back to fiscal 2015, with figures through fiscal 2018. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.